Bottom line
Is MMRAX a good fund? The bottom line
MMRAX is the Class A share class of NYLI Moderate Allocation Fund, a managed allocation / balanced mutual fund from New York Life Investments.
It charges 0.88% — about $88 a year on every $10,000 invested, cheaper than 53% of allocation / balanced funds we track.
It returned +7.7% over one year, +5.0% a year over five years, +6.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $808 million in net assets and 36 holdings, its largest position is NYLIM U.S. Government Liquidity Fund (9.7%) and the top 10 make up 61.8% of the portfolio.
This share class carries a front-end sales charge of up to 3%; a no-load class or ETF alternative can avoid it.
What to watch
- Concentrated: top 10 holdings are 61.8% of assets
- Front-end sales load up to 3%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What MMRAX invests in
The Fund seeks long-term growth of capital and, secondarily, current income.
"The Fund is a ""fund of funds"" that seeks to achieve its investment objective by investing primarily in mutual funds and exchange-traded funds managed by New York Life Investment Management or its affiliates (the ""Underlying Funds""). The Underlying Funds are described and offered for direct investment in separate prospectuses. The Fund is designed for investors with a particular risk profile as represented by the asset class allocations described below, and invests in a distinct mix of Underlying Funds. The Fund seeks to achieve its investment objective by normally investing approximately 60% (within a range of 50% to 70%) of its assets in Underlying Equity Funds and approximately 40% (within a range of 30% to 50%) of its assets in Underlying Fixed-Income Funds. The Fund may invest approximately 15% (within a range of 5% to 25%) of its assets in Underlying International Equity…
From the fund's prospectus (filed Feb 26, 2026).
MMRAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MMRAX | +7.7% | +5.0% | +6.2% |
| Allocation / Balanced median | +11.0% | +5.7% | +6.7% |
Source: Fund prospectus, as of Dec 31, 2025
What MMRAX costs
On a $10,000 investment, MMRAX's 0.88% expense ratio costs about $88 a year. The prospectus estimates $1,352 in total costs over 10 years (assuming 5% annual returns). The median allocation / balanced fund charges 0.91%.
MMRAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | NYLIM U.S. Government Liquidity Fund | 9.73% |
| 2 | NYLIM US Large Cap R&D Leaders ETF | 8.20% |
| 3 | NYLIM MacKay Core Plus Bond ETF | 6.61% |
| 4 | NYLIM MacKay Total Return Bond Fund | 6.61% |
| 5 | NYLIM Candriam U.S. Mid Cap Equity ETF | 5.39% |
| 6 | NYLIM Candriam U.S. Large Cap Equity ETF | 5.20% |
| 7 | NYLIM MacKay U.S. Infrastructure Bond Fund | 5.14% |
| 8 | NYLIM MacKay Securitized Income ETF | 5.13% |
| 9 | NYLIM Floating Rate Fund | 5.04% |
| 10 | NYLIM WMC Growth Fund | 4.75% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 61.8% of the fund. See all top 25 holdings and asset mix →